Adagrasib - Mirati Therapeutics
Alternative Names: KRAZATI; MRTX 849Latest Information Update: 03 Apr 2024
At a glance
- Originator Array BioPharma; Mirati Therapeutics
- Developer Aadi Bioscience; Mirati Therapeutics; Novartis; University of Texas M. D. Anderson Cancer Center; ZAI Lab
- Class Acetonitriles; Antineoplastics; Halogenated hydrocarbons; Naphthalenes; Piperazines; Pyridones; Pyrimidines; Pyrrolidines; Small molecules
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Non-small cell lung cancer
- Preregistration Colorectal cancer
- Phase II Solid tumours
- Phase I Pancreatic cancer
- Preclinical Bladder cancer
Most Recent Events
- 01 Apr 2024 Zai Lab announces intention to submit NDA to China's National Medical Products Association for Non-small cell lung cancer (Second-line therapy or greater) in 2024
- 01 Apr 2024 Adverse events and efficacy data from the phase-III KRYSTAL-12 trial in Non-small cell lung cancer released by Zai Lab
- 27 Feb 2024 Zai Lab announces intention to submit NDA to NMPA for Non small cell lung cancer